Neoadjuvant endocrine therapy for breast cancer: Medical perspectives

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4388s-4391s

  Ellis, Matthew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; FULVESTRANT; LETROZOLE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; INCIDENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HORMONES; HUMANS; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN;

EID: 0035664709     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Surgery as an adjunct to hormone therapy of breast cancer
2. Preoperative endocrine therapy for older women with breast cancer: Renewed interest in an old idea
3. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only
4. The effects of neoadjuvant anastrozole (arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study
5. Neoadjuvant Arimidex or Tamoxifen alone or in combined, for breast cancer (IMPACT): PgR-related reductions in Proliferation Marker Ki67
6. Phase IIb Study of Neoadjuvant Exemestane (EXE) in locally advanced breast cancer
7. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
8. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
9. A randomized Double Blind Multicenter Study of Preoperative Tamoxifen versus Letrozole for Postmenopausal Women with ER and/or PgR positive breast cancer ineligible for breast conserving surgery. Correlation of clinical response and tumor gene expression and proliferation
10. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2 positive, estrogen receptor positive primary breast cancer: Evidence from a phase 3 randomized trial
11. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
12. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
13. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
14. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
15. Genes that co-cluster with estrogen receptor α in microarray analysis of breast biopsies